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Introduction: Two protocols were developed to guide the use of subdissociative dose ketamine 
(SDDK) for analgesia and dissociative sedation ketamine for severe agitation/excited delirium in the 
emergency department (ED). We sought to evaluate the safety of these protocols implemented in 18 
EDs within a large health system. 
Methods: We conducted a retrospective chart review to evaluate all adult patients who received 
intravenous (IV) SDDK for analgesia and intramuscular (IM) dissociative sedation ketamine for 
severe agitation/excited delirium in 12 hospital-based and six freestanding EDs over a one-year 
period from the protocol implementation. We developed a standardized data collection form and 
used it to record patient information regarding ketamine use, concomitant medication use, and any 
comorbidities that could have impacted the incidence of adverse events. 
Results: Approximately 570,000 ED visits occurred during the study period. SDDK was used in 210 
ED encounters, while dissociative sedation ketamine for severe agitation/excited delirium was used 
in 37 ED encounters. SDDK was used in 83% (15/18) of sites while dissociative sedation ketamine 
was used in 50% (9/18) of sites. Endotracheal intubation, non-rebreather mask, and nasal cannula 
≥ four liters per minute were identified in one, five, and three patients, respectively. Neuropsychiatric 
adverse events were identified in 4% (9/210) of patients who received SDDK. 
Conclusion: Patients experienced limited neuropsychiatric adverse events from SDDK. Additionally, 
dissociative sedation ketamine for severe agitation/excited delirium led to less endotracheal 
intubation than reported in the prehospital literature. The favorable safety profile of ketamine use in 
the ED may prompt further increases in usage. [West J Emerg Med. 2020;21(2):XX-XX.]
INTRODUCTION 
Ketamine is an N-methyl-D-aspartate receptor antagonist 
that exhibits dissociative sedation and analgesic properties 
and is commonly used in procedural sedation and induction 
settings.1-3 Additionally, ketamine has been explored as novel 
therapy for analgesia and severe agitation/excited delirium. 
Multiple studies have described the efficacy and safety of 
subdissociative-dose ketamine (SDDK) for analgesia in the 
emergency department (ED), typically with dosing regimens 
of 0.1-0.3 milligrams per kilogram (mg/kg) administered 
intravenously (IV).4-9 Dissociative sedation ketamine, typically 
defined as 3-5 mg/kg given intramuscularly (IM),10-12 has been 
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Population Health Research Capsule
What do we already know about this issue?
The use of subdissociative dose ketamine 
(SDDK) and dissociative sedation ketamine may 
lead to serious respiratory, cardiovascular, and 
neuropsychiatric adverse events.
What was the research question?
To describe the incidence of severe adverse 
events after ketamine use in the ED and 
adherence to ketamine dosing protocols.
What was the major finding of the study?
Dissociative sedation ketamine led to less 
intubation than reported in pre-hospital studies 
and SDDK led to limited toxicities.
How does this improve population health?
Ketamine used for analgesia or severe agitation/
excited delirium leads to limited adverse events 
and is a viable option when dosed based on our 
health system’s ketamine protocols.
studied for severe agitation/excited delirium in the prehospital 
setting.12-14 Ketamine use for this indication has also been 
studied in a limited number of patients in single-center 
EDs.15,16 Adequate sedation is necessary to prevent severe 
agitation/excited delirium complications such as metabolic 
abnormalities, cardiac arrest, and death.11 
However, ketamine administration may contribute to 
serious respiratory, cardiovascular, and neuropsychiatric 
adverse events.8,10,12 Cole et al. reported intubation rates of 
39% for severely agitated patients who received ketamine 5 
mg/kg IM vs 4% for those who received haloperidol 10 mg 
IM in the prehospital setting.13 These authors also reported 
intubation rates of 57% in profoundly agitated patients who 
received ketamine in the prehospital setting.14 SDDK use may 
also lead to neuropsychiatric adverse events such as mood 
changes, dysphoria, confusion, and hallucinations.4-6, 16 To 
assist emergency medicine (EM) prescribers in safely using 
ketamine, our emergency services attending physicians and 
pharmacists developed two ED ketamine protocols for these 
two indications. 
Previous single-center studies have described the benefits 
and risks of SDDK for analgesia and dissociative sedation 
ketamine for severe agitation/excited delirium, but the 
optimal dosing range and administration method of SDDK 
to minimize adverse effects is unclear.8-9, 17-18 Additionally, 
limited, single- center studies have assessed the safety of 
IM ketamine for severe agitation/excited delirium in the 
prehospital setting and ED.12-16  We designed this multicenter 
study to provide further insight into the safety of ketamine 
use in the ED for these two novel indications across a broad 
spectrum of EDs in a variety of settings.
Our goal was to evaluate the safety of SDDK for 
analgesia and dissociative sedation ketamine for severe 
agitation/excited delirium in patients at 18 EDs of a large, 
integrated health system. The primary objective of this study 
was to describe the incidence of serious respiratory and 
cardiovascular adverse events requiring intervention within 
two hours after ketamine administration. Secondary objectives 
included describing the incidence of neuropsychiatric adverse 
events after SDDK administration during the ED encounter; 
determining the percentage of ketamine orders in the ED 
for analgesia or severe agitation/excited delirium that were 
adherent to the approved protocols; and evaluating real-
world ketamine use in a large, integrated health system with a 
diverse group of providers.
Materials and Methods 
This study was a multicenter, retrospective, electronic 
medical chart review that evaluated the safety of SDDK for 
analgesia and dissociative sedation ketamine for agitation/
excited delirium in ED settings. The authors of this study 
have no conflict of interest, and our institutional review board 
approved this study. The study sites included 12 hospital-
based EDs and six freestanding EDs with a combined annual 
census of over half a million ED visits. The hospital-based 
EDs include a quaternary care, academic medical center, a 
Level 1 trauma center, and 10 community hospitals, including 
two Level 2 trauma centers, in both suburban and urban 
locations. Medical care at the study sites was provided by 
emergency physicians, medical residents, advanced practice 
registered nurses, and physician assistants. The health 
system uses a comprehensive, integrated electronic health 
record (EHR) (EPIC, Verona, WI) at all hospital-based and 
freestanding EDs.  
In 2017 two ketamine protocols were developed to 
provide guidance for the use of SDDK for acute pain and 
IM ketamine for dissociative sedation for severe agitation/
excited delirium at all EDs across the enterprise. The protocols 
included indications for therapy as well as recommended 
dosage regimens and monitoring parameters. See Table 1 for 
treatment protocol details and treatment indication definitions. 
The ketamine protocol recommendations were developed by 
our institution’s emergency physicians, pharmacists, midlevel 
providers, and nurses based on currently available literature 
for ketamine use for these two indications and ketamine’s 
pharmacokinetic and pharmacodynamics profile. 
Emergency providers and nursing were educated via email 
communication and staff meetings regarding the data supporting 
the new ketamine protocols and the operational changes 
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Subdissociative-dose ketamine (SDDK) 
for analgesia Ketamine for severe agitation/excited delirium
Indications First-line analgesic therapy for management 
of severe pain in the following scenarios: 
• Acute pain secondary to traumatic injury 
• Acute pain in patients with documented 
allergy/intolerance to parenteral opioid 
therapy
• Chronic pain in patients who are not 
candidates for opioid or NSAID therapy
Adjunct analgesic therapy for the 
management of severe pain in ED patients 
who failed to achieve therapeutic response 
with parenteral opioid therapy
First-line pharmacologic monotherapy for adult patients 
with severe agitation, excited delirium, and violent/self-
destructive behavior who meet the following criteria:
• Patient poses an immediate threat to patient and 
healthcare provider safety (RASS score of +4) 
• Failure and/or futility of alternative non-
pharmacologic de-escalation strategies 
• Absence of IV access 
• Not a candidate for intramuscular antipsychotics and/
or benzodiazepines due to unacceptably protracted 
onset of action
Contraindications Unstable vital signs
• Systolic blood pressure > 180 mmHg 
• Heart rate > 150 beats per minute 
• Respiratory rate < 10 or > 30 
Suspected acute coronary syndrome
Acute decompensated heart failure 
Unstable dysrhythmia
Acute head or ocular trauma 
Suspected elevated intracranial pressure 
History of schizophrenia or other psychosis 
Active psychosis
None
Dosing regimen 
and administration
0.2 – 0.3 mg/kg (up to a max  dose of 25 mg)
Administered as slow IV push over 5 minutes
Dose may be repeated once in 30 minutes
4 mg/kg IM up to max  single dose of 500 mg 
Dosing weight can be estimated if actual weight unavailable
Immediate availability of advanced airway equipment
Patient monitoring Vital signs (including pain assessment) at 
baseline, 15 minutes, and 30 minutes after 
each dose followed by routine nursing care 
per department protocol
Continuous pulse oximetry for at least 30 
minutes after dose administration 
Telemetry for at least 30 minutes after dose 
administration
Immediate availability of ED attending 
physician for at least 30 minutes
Continuous direct patient observation for minimum of 
15 minutes 
Continuous pulse oximetry, cardiac monitor, and end-
tidal CO2 monitoring (if available) 
Removal of physical restraints 
Supine patient positioning with elevation of head of bed 
at 30°
Table 1. Ketamine treatment protocols.
ED, emergency department; NSAID, Nonsteroidal anti-inflammatory drugs; RASS, Richmond Agitation-Sedation Scale; IV, intravenous; 
mmHg, millimeters of mercury; mg/kg, milligrams per kilogram; CO2, carbon dioxide.
associated with them. Afterward, the ketamine protocols were 
implemented on May 9, 2017. SDDK ketamine would be dosed 
0.2-0.3 mg/kg, maximum dose 25 mg, as a slow IV push over 
five minutes with a potential repeated dose in 30 minutes. 
Ketamine for severe agitation/delirium would be dosed 4 mg/
kg IM once, with a maximum dose of 500 mg. Providers were 
reminded monthly of the new protocol doses and indications 
through emails, especially with consideration of the opioid 
crisis and the desire to use alternative, non-opioid analgesics. 
Adult patients, at least 18 years old, who received IV 
SDDK for analgesia and/or IM dissociative sedation ketamine 
for severe agitation/excited delirium at any study ED from 
May 9, 2017–May 9, 2018, were included in the study. 
Exclusion criteria included the following: age <18 years old; 
administration of ketamine for indications other than analgesia 
or severe agitation/excited delirium (e.g., rapid sequence 
intubation, procedural sedation, etc.); or administration of 
ketamine via route other than IV or IM. Four of the ED sites 
(one hospital-based ED and three freestanding EDs) were not 
using the integrated health record until September 29, 2017; 
therefore, patients were eligible for study inclusion only 
between September 29, 2017–May 9, 2018, at these four study 
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EDs. An ED agitation protocol order set was built into our 
EHR that enabled the EM provider to select severe agitation/
excited delirium as the indication, which would provide a 
calculated dose of ketamine 4 mg/kg IM if this drug were 
selected. A specific order set was not created for ketamine 
used for analgesia.  
We conducted a query of our EHR to identify all patients 
who received either IV bolus or IM ketamine at a study 
ED within the study period. A standardized electronic data 
collection form was developed within Research Electronic 
Data Capture (REDCap, Nashville, TN), a secure data 
collection tool. A single investigator, H.M., a clinical 
pharmacy resident, manually conducted chart review within 
the EHR to collect data points such as ketamine regimen 
details; vital sign data; psychiatric comorbidities; concomitant 
medications (benzodiazepines, antipsychotics, opioids, and 
antihistamines) administered within one hour before and 
two hours after ketamine use; predefined ketamine-related 
adverse events; and additional relevant points for all eligible 
patients. Adverse event data was identified through review of 
physician and allied health documentation during the ED visit, 
as well as review of the medication administration record and 
respiratory documentation flowsheets within the EHR. Data 
collected in the respiratory documentation flowsheets included 
the patient’s respiratory status (eg, endotracheal intubation 
[ETI], bag valve mask, bilevel positive airway pressure 
[BiPAP], non-rebreather mask, nasal cannula [NC], or room 
air), and the timing of respiratory intervention, if applicable. 
A single investigator collected and reviewed all data to ensure 
consistency in data interpretation. 
The primary outcome was to describe the incidence of 
severe respiratory and cardiovascular adverse events after 
ketamine administration. We defined severe respiratory 
adverse events as use of an advanced airway such as ETI, 
non-invasive positive pressure ventilation (bag valve mask, 
BiPAP, continuous positive airway pressure), non-rebreather 
mask, and/or escalation from baseline oxygen requirements 
to at least four liters (L) or more per minute via NC within 
two hours following administration of ketamine dose. Severe 
cardiovascular adverse events were defined as elevated 
blood pressure requiring IV antihypertensive medication(s) 
or new dysrhythmia requiring electrical cardioversion or 
pharmacological rate and/or rhythm control within two hours 
following administration of a ketamine dose. 
Secondary outcomes included describing the incidence 
of neuropsychiatric adverse events after SDDK for analgesia 
administration and determining the percentage of ketamine 
orders for both indications in the ED that were adherent to 
the approved protocols. We defined neuropsychiatric adverse 
events as hallucinations, dysphoria, delusions, and/or any 
other mood change documented at any time during the ED 
visit following administration of a ketamine dose. Protocol 
adherence was defined as administering ketamine without 
protocol contraindications and using dosing regimens within 
the approved dose ranges and frequencies. There were no 
contraindications listed for using ketamine for severe agitation/
excited delirium since acute interventions for this emergent 
condition are time sensitive, and an accurate medical history is 
often difficult to obtain. We analyzed all data descriptively.     
RESULTS
During the study period, we identified 762 ED encounters 
with ketamine administration; 515 did not meet study 
inclusion criteria. A total of 247 ED encounters (210 SDDK 
and 37 dissociative sedation ketamine) were included in 
the study. There were 170 unique patient encounters as 13 
patients within the SDDK group had repeated ED visits. These 
13 patients accounted for 53/210 (25.2%) of all SDDK ED 
encounters. All patient characteristics reported were calculated 
based on unique patient encounters. The median age was 43 
years of age (interquartile range [IQR]: 30-54) in the SDDK 
group and 39 (IQR: 31-48) in the dissociative sedation group. 
Median baseline blood pressure was 130/81 millimeters of 
mercury (mmHg) (IQR: 118-149.5/71-90.5 mmHg) prior 
to ketamine administration in the SDDK group. The most 
frequently used concomitant medications for the SDDK group 
were opioids (30%), while benzodiazepines (54.1%) were 
more commonly used in the dissociative sedation ketamine 
group. Table 2 summarizes patient demographics for each 
ketamine group.
In the SDDK group, the median ketamine dose was 20 
mg (IQR: 16.1-25) IV with a median weight-based dose of 
0.26 mg/kg (IQR: 0.2-0.3) IV. In the severe agitation/excited 
delirium group, the median ketamine dose was 242.4 mg (IQR: 
124.7–319.4) IM with a median weight-based dose of 3.2 mg/
kg (IQR: 1.89-4.0) IM. Fifteen out of 18 (83%) ED sites used 
SDDK for analgesia while 9/18 (50%) used dissociative sedation 
ketamine for severe agitation/delirium (Table 3). The distribution 
of ketamine use by type of ED is also described in Table 3.
For the primary outcome, serious respiratory adverse 
events were identified in 1% (2/210) of patients in the SDDK 
group and 16.2% (6/37) of patients in the dissociative sedation 
group. Additionally, serious cardiovascular adverse events 
were identified in 0.5% (1/210) of patients in the SDDK group. 
Examples from the SDDK group included three different patients 
who either received NC oxygen ≥ 4 L/minute (min), required a 
non-rebreather mask, or were given IV antihypertensive therapy 
for elevated blood pressures. Examples from the dissociative 
sedation group included one patient who received ETI, three 
patients who received a non-rebreather mask, and two patients 
who received NC oxygen ≥ 4 L/min. The patient who received 
ETI initially came in with seizures and had no history of 
substance abuse or psychosis documented. 
In the SDDK group 4.3% (9/210) of patients experienced 
neuropsychiatric adverse events. Patients described these 
neuropsychiatric adverse events as feeling “out of it,” 
Articles in Press 5 Western Journal of Emergency Medicine
Mo et al. Ketamine Safety and Use in the ED
Patient characteristics SDDK IV for analgesia (n=210) Ketamine IM for agitation/delirium  (n=37)
No. of ED encounters 210 37
Age, median (IQR), years 43 (IQR: 30-54) 39 (IQR: 31-48)
Sex, male (%) 39 70
Weight, median (IQR), kg 79.9 (65.8-90.7) 77.1 (IQR: 68-99.8)
History of psychosis (%) 11.9 40.5
History of illicit drug use or alcohol abuse (%) 22.4 59.5
Systolic blood pressure, median (IQR),  mmHg* 130 (118-149.5) N/A
Diastolic blood pressure, median (IQR),  mmHg* 81 (71-90.5) N/A
Pulse rate, median (IQR),  beats/min* 83 (IQR: 70-98) N/A
O2 saturation, median (IQR), %* 98 (IQR: 97-100) N/A
Concomitant medications† (%)
Antihistamines 10.0 24.3
Antipsychotics 3.3 35.1
Benzodiazepines 12.4 54.1
Opioids 30.0 5.4
Table 2. Baseline patient demographics.
*Baseline vitals prior to ketamine administration
†One hour before or two hours after ketamine administration
SDDK, subdissociative-dose ketamine; IV, intravenous; IM, intramuscular; ED, emergency department; IQR, interquartile range; kg, 
kilogram; mmHG, millimeters of mercury; O2, oxygen.
“uncontrolled,” confused, and anxious. One patient experienced 
hallucinations. The same patient who experienced the 
serious cardiovascular adverse event also experienced an 
emergence reaction and neuropsychiatric adverse event. No 
neuropsychiatric adverse events required intervention. Adverse 
events are summarized in Tables 4-6.
For the secondary outcome of protocol adherence, 80% 
of patients (167/210) in the SDDK group and 32% (12/37) 
in the dissociative sedation group met adherence criteria 
(administering SDDK without protocol contraindications 
or ketamine for either indications within the approved 
dose ranges and frequencies).  Eight patients who received 
SDDK had a systolic blood pressure greater than 180 and 
one patient presented with head trauma, both of which are 
protocol contraindications for SDDK. A total of 11.4% of 
patients (24/210) in the SDDK group and 54.1% (20/37) 
in the dissociative sedation ketamine group received doses 
below the recommended range. The recommended dose is 
0.2-0.3 mg/kg IV for SDDK, maximum dose 25 mg, and 
can be repeated once in 30 minutes, and 4 mg/kg IM once 
for severe agitation/excited delirium. Additionally, 3.8% of 
patients (8/210) in the SDDK group received ketamine above 
0.3 mg/kg IV or higher than the maximum recommended 
single dose of 25 mg IV. Five of 37 patients (13.2%) 
received dissociative sedation ketamine doses greater than 
4 mg/kg IM. A summary of ketamine protocol adherence is 
described in Table 7.
LIMITATIONS
This study was retrospective and relied on accurate 
documentation of adverse events. Variable documentation may 
have impacted the results identified. However, this limitation 
was minimized by using objective outcome measures such 
as specific respiratory and medication interventions to define 
adverse events. Neuropsychiatric adverse events may also have 
been under-reported considering that ED nursing, respiratory 
therapy, and/or physician documentation was the primary source 
for identification. The descriptiveness of these side effects 
reported were also limited by chart documentation. However, 
none of the identified neuropsychiatric adverse events required 
intervention, suggesting that the adverse effects observed were 
mild and self-limiting. Additional limitations include the data 
review by a single abstractor, who potentially may have not 
captured all adverse events. Furthermore, there was no control 
group to calculate a confidence interval and determine whether 
these adverse events identified were statistically significant. Last, 
data was not available to further characterize patients who met 
exclusion criteria. 
DISCUSSION
 In this multicenter pragmatic study, the use of SDDK 
for analgesia and dissociative sedation dosing for severe 
agitation/excited delirium resulted in a lower incidence of 
serious respiratory adverse events than previously reported. 
In patients receiving dissociative sedation ketamine for severe 
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Ketamine SDDK IV for analgesia Ketamine IM for agitation/delirium
Dose in mg, median (IQR) 20 (IQR: 16.1-25) 242.4 (IQR 124.7-319.4)  
Dose in mg/kg, median (IQR) 0.26 (0.2-0.3) 3.2 (1.89-4)
Unique ED encounters 170 37
No. patients with repeated ED encounters 13, accounting for 40 ED encounters 0
No. ED locations using ketamine (%) 15 out of 18 (83) 9 out of 18 (50)
ED Type
Hospital-based ketamine patients 196 37
Freestanding ketamine patients 14 0
Table 3. Ketamine utilization.
SDDK, subdissociative-dose ketamine; IV, intravenous; IM, intramuscular; ED, emergency department; IQR, interquartile range; 
mg, milligram; kg, kilogram; no., number.
SDDK IV for analgesia (n=210) Ketamine IM for agitation/ delirium (n=37)
Respiratory 2 (1.0%) 6 (16.2%)
Endotracheal intubation 0 1† (2.7%)
Bag valve mask 0 0
BiPAP 0 0
Non-rebreather mask 1 (0.5%) 4† (10.8%)
Nasal cannula O2 ≥ 4 L/min 1 (0.5%) 2 (5.4%)
Cardiovascular 1* (0.5%) 0
Neuropsychiatric 9* (4.3%) 0
†Indicates one patient required both non-rebreather mask use and endotracheal intubation
*Indicates one patient experienced a cardiovascular and neuropsychiatric adverse event
SDDK, subdissociative-dose ketamine; IV, intravenous; IM, intramuscular; BiPAP, bilevel positive airway pressure.
Table 4. Adverse events.
agitation/excited delirium, 16.2% of patients experienced 
serious respiratory adverse events. However, only one of 
these patients required ETI yielding an intubation rate of only 
2.7% within this treatment group. In contrast, Cole et al.’s 
single-center studies reported that intubation rates were 39% 
in severely agitated patients and 57% in profoundly agitated 
patients who received ketamine 5 mg/kg IM in the prehospital 
setting.13-14 These studies raised concern about the safety of 
ketamine use. The differences in intubation rates between our 
study and Cole et al.’s studies may be attributed to a number 
of factors. Ketamine administration in the prehospital setting 
for severe agitation/excited delirium results in the arrival of 
a fully dissociated patient at the time of ED presentation, 
which may contribute to a higher probability of a respiratory 
intervention provided by the receiving emergency physician. 
In our study, patients were evaluated by an emergency 
physician prior to the institution of dissociative sedation, 
which may have allowed for more appropriate selection 
of patients and closer monitoring of patients’ respiratory 
status following administration of ketamine. The patients 
in our study also received a lower median dose of 3.2 mg/
kg IM (IQR: 1.9-4.0 mg/kg), compared to an average of 5 
mg/kg in the Cole et al. studies. The lower ketamine doses 
also may have led to a decreased incidence of respiratory 
depression requiring ETI. Furthermore, the use of concomitant 
medications with sedative potential in the prehospital setting 
may have also led to an increased number of respiratory 
adverse events. Cole et al. reported that patients in their 
study had positive urine drug screen results for opioids 
(21%), diphenhydramine (12%), antipsychotics (15%), and 
benzodiazepines (18%).13 The amount, frequency, and timing 
of these administrations is unknown. 
Although our study did not evaluate the use of prehospital 
medications, only 5.4% of our patients received opioids one 
hour before or two hours after ketamine use in the ED. Of 
note, controversy does exist as to whether intubation itself is 
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considered an adverse event given that these patients were 
severely agitated and at high risk of harm to self or others 
where the only alternative was to intubate and sedate to 
ensure patient safety. Finally, the increased publicity around 
ketamine usage in the ED literature may have led to more 
familiarity with its pharmaceutical properties and concomitant 
risks. Our protocol required that once sedation occurred, a 
full complement of monitoring be deployed including cardiac 
monitoring, pulse oximetry, and presence of nursing at 
bedside, similarly to procedural sedation practices.
SDDK use led to few serious respiratory adverse events 
requiring intervention. One patient required NC ≥ 4 L/min 
and a second patient required the use of a non-rebreather 
mask; none of the patients required ETI. Both of these patients 
received just one dose of ketamine and met all protocol 
adherence criteria. However, both patients also received one 
dose of fentanyl IV 50 micrograms and morphine IV 4 mg, 
respectively. Additionally, one of these patients had a history 
of drug and/or alcohol abuse, which may have impacted the 
occurrence of adverse events. Although the use of opioids 
and having a history of drug and/or alcohol abuse may have 
contributed to the need for respiratory intervention, these 
findings suggest that close patient monitoring of respiratory 
status with SDDK may be warranted. 
One patient in the SDDK group (0.5%) also experienced 
elevated blood pressures following ketamine administration, 
which required IV antihypertensive therapy despite the 
absence of any protocol contraindications. This patient’s 
blood pressure went from a baseline of 161/86 mmHg to 
205/164 mmHg after ketamine administration. The potential 
for ketamine to contribute to elevated blood pressure and 
heart rate has been well established. Review of vital signs 
prior to dose administration to determine the absence of 
hemodynamic instability and monitoring vital signs after dose 
Patient 1* Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age, years 42 34 54 54 30 31
Gender Male Male Female Female Male Male
Weight, kg 79.4 86.2 55.8 68 162 113.4
History of psychosis No No Yes Yes No Yes
Illicit drug/ alcohol abuse No Yes Yes Yes Yes No
Number of ketamine doses 
during ED visit
3 1 1 1 1 2
Ketamine dose, mg 238.2 IV, 158.8 
IV, and 317.6 IM
300 IM 223.2 IM 300 IM 150 IM 113.4 IM x2
Ketamine dose, mg/kg 2 IV, 3 IV, and 
4 IM 
3.48 IM 4 IM 4.4 IM 0.92 IM 1 IM x2
Baseline supplemental 
oxygen 
No No No No No No
Concomitant medications 
1 hour before or 2 hours 
after ketamine use
Lorazepam IV 1 
mg x1 and 2mg 
x2
Haloperidol IM 
5 mg x1  
None Lorazepam IM 2 
mg x1
Diphenhydramine 
IV 50 mg x1
Lorazepam 
IV 1 mg x2
None Lorazepam IM 2 
mg x1
AE identified Non-rebreather 
mask and 
endotracheal 
intubation
Non-
rebreather 
mask
Non-rebreather 
mask
Non-
rebreather 
mask
NC O2 ≥ 4 L/min NC O2 ≥ 4 L/min
Time (min) between AE 
and ketamine use
4 min after first 
ketamine IV 
dose and 120 
min after IM 
ketamine dose
12 104 44 41 42 min after 
second 
ketamine dose
*Required endotracheal intubation
Kg, kilogram; ED, emergency department; mg, milligram; IV, intravenous; IM, intramuscular; AE, adverse event; NC, nasal cannula; O2, 
oxygen; L, liters; min, minute.
Table 5. Respiratory and cardiovascular adverse event patient cases: dissociative sedation ketamine.
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Patient 1 Patient 2 Patient 3
Age, years 70 28 66
Gender Male Male Female
Weight, kg 69.4 149.7 53.1
Psychosis No No No
Illicit drug/ alcohol abuse No Yes No
Number of ketamine doses 1 1 1
Ketamine dose, mg 20.82 IV 25 IV 15 IV
Ketamine dose, mg/kg 0.3 IV 0.17 IV 0.28
Baseline supplemental oxygen No No No
Concomitant medications 1 hour before or 
2 hours after ketamine use
Fentanyl 
IV 50 mcg x1
Morphine IV 4 mg x1 Morphine IV 5 mg x1
AE identified Non-rebreather mask NC O2 ≥ 4 L/min Elevated BP receiving IV 
labetalol 10 mg x1 (BP increased 
to 205/164 from 161/86 mmHg)
Time (min) between AE and ketamine use 32 9 76
Table 6. Respiratory and cardiovascular AE patient cases: subdissociative ketamine.
Kg, kilogram; mg, milligram; IV, intravenous; mcg, microgram; AE, adverse effect; NC, nasal cannula; L, liter; min, minute; BP, blood pressure.
administration is indicated.  
SDDK use also led to limited and non-severe 
neuropsychiatric adverse events in 4.3% of patients. However, 
Motov et al. reported higher rates of mood changes (13%) and 
disorientation (29%) in patients who received 0.3 mg/kg 
(mean 21.8 mg, standard deviation 4.9 mg) of ketamine IV 
push over 3-5 minutes.8 In contrast, Sin et al. reported 
neuropsychiatric adverse advents in 3% of patients who 
received ketamine IV 0.3 mg/kg IV piggyback over 15 
minutes.16 Neither study included patients with a past medical 
history of psychiatric illness or substance abuse or described 
concomitant medications used outside of the protocol.8,16 
Concomitant medications and comorbidities may lead to an 
increase in adverse events. 
Due to the retrospective design of our study, the lower 
incidence of neuropsychiatric adverse events reported may 
have been attributed to incomplete documentation of adverse 
events in the EHR. The lower rates of neuropsychiatric adverse 
events in our study may also have been due to our ketamine 
single-dose cap of 25 mg and the requirement of a slow IV push 
administration over at least five minutes. Our multicenter study 
results support that SDDK use led to minor neuropsychiatric 
adverse events that did not require intervention, which aligns 
with previously published, single-center studies.5,8  
Despite frequent reminders, the protocols were not used 
at all of the ED sites in our enterprise. This probably reflects 
the reality of knowledge translation and willingness of more 
experienced physicians to try new medications with which 
they are less familiar or their comfort with more conventional 
therapy for analgesia such as opioids or benzodiazepines and 
haloperidol for agitation. While ketamine usage has been 
increasingly touted in Free Open Access Medication Education 
(FOAMed) and other social media, the vocal users may be in 
more academic settings or accustomed to trying novel therapies. 
The strength of our study lies in its real-world experience across 
a diverse group of providers and ED sites. This study should 
help alleviate some concerns of those providers that the therapy 
is safe and effective even in small EDs.
The protocol adherence for SDDK was 80%, while 
dissociative sedation ketamine was 32%. The decreased 
protocol adherence was attributed primarily to patients 
receiving ketamine below the recommended doses. This can 
paradoxically be harmful as partially dissociated patients 
have more neuropsychiatric effects, which may increase 
agitation. This is perhaps due to the ED prescribers not being 
as comfortable with ordering higher doses of ketamine. 
Additionally, it is difficult to collect an accurate weight for 
severely agitated patients who present to the ED; thus, empiric 
dosing may have been based on estimated weight for a number 
of patients, potentially contributing to dosing variance beyond 
the protocol-recommended dosing range. 
Several patients also received ketamine doses above the 
recommended range. This may not portend harm as once 
dissociation is achieved, there is no further depth to sedation 
with increased ketamine administration. Additionally, protocol 
variance may have also been impacted by the specific ED 
site and emergency physician. Three out of the 18 EDs 
accounted for 70% of IM ketamine use for severe agitation/
excited delirium. This protocol required attending physician 
administration of the drug, which may have limited its use.  
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Proportion of ketamine regimens adherent to 
health-system protocols SDDK IV for analgesia Ketamine IM for agitation/ delirium
Without protocol contraindications 201/210 (96%)
Received ketamine when 
SBP>180 mmHg: 8 
Received ketamine presenting with head 
trauma: 1
Not applicable
Dosing regimens within the approved dose 
ranges and frequencies based on our institution’s 
ketamine protocols (refer to Table 1)
175/210 (83%)
Dosed below range: 24
Dosed above range: 8
Received > 2 doses in same ED visit: 2
Received ketamine <30 min apart: 1
12/37 (32%)
Dosed below range: 20
Dosed above range: 5
Total adherence 167/210* (80%) 12/37 (32%)
Table 7. Ketamine protocol adherence.
*One patient received ketamine with an SBP > 180 mmHg and above the recommended dose
SDDK, subdissociative-dose ketamine; IV, intravenous; IM, intramuscular; SBP, systolic blood pressure; mmHG, milligrams of mercury; 
ED, emergency department; min, minute.
CONCLUSION
Dissociative sedation ketamine dosed at 4 mg/kg IM for 
severe agitation can result in serious respiratory adverse events. 
However in our experience, this occurred less frequently 
than previously reported in single-center studies. When used 
at subdissociative-doses for analgesia at 0.2-0.3 mg/kg and 
administered as slow IV push over five minutes, ketamine is 
associated with minor and self-limited neuropsychiatric adverse 
events that resolve without further intervention. In summary, 
the overall favorable safety profile of ketamine use as described 
in our experience in a number of diverse ED settings supports 
a more widespread use of SDDK and dissociative dosing for 
acute agitation. Further research is needed to address barriers 
that prevent more extensive usage of ketamine by ED providers.
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